Critical Assessment of Noninvasive Prenatal Testing: Before or after Anomaly Scan

@inproceedings{Zalel2018CriticalAO,
  title={Critical Assessment of Noninvasive Prenatal Testing: Before or after Anomaly Scan},
  author={Yaron Zalel},
  year={2018}
}
Noninvasive prenatal test (NIPT) analyzes cell-free DNA (cfDNA) in the maternal serum. Approximately, 3–15% of cfDNA in the maternal blood is of fetal origin. The NIPT examination, based on the existence of this cfDNA, is accurate in screening for Down syndrome and less for other trisomies, as well as other structural chromosomal abnormalities. The commercial companies offer this technique as early as 10 weeks of gestation. The purpose of this critical assessment is to challenge the timing of… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Prenatal aneuploidy screening using cell-free DNA.

  • American journal of obstetrics and gynecology
  • 2015
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Non-invasive prenatal testing--it's all a matter of timing.

  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2015